Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-β gene

Journal of Immunology

Volumn 177, Issue 6, 2006, Pages 3564-3576

  Shibata, Satoko ^a   Okano, Shinji ^a   Yonemitsu, Yoshikazu ^a   Onimaru, Mitsuho ^a   Sata, Shihoko ^a   Nagata Takeshita, Hiroko ^a   Inoue, Makoto ^b   Zhu, Tsugumine ^b   Hasegawa, Mamoru ^b   Moroi, Yoichi ^a   Furue, Masutaka ^a   Sueishi, Katsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b DNAVEC Corporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BETA INTERFERON; CANCER VACCINE; CD40 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GREEN FLUORESCENT PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SENDAI VIRUS; TUMOR IMMUNITY; VIRUS RECOMBINANT;

EID: 33748501271     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.6.3564     Document Type: Article

References (41)

1. Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183: 87-97.
2. Berzofsky, J. A., M. Terabe, S. Oh, I. M. Belyakov, J. D. Ahlers, J. E. Janik, and J. C. Morris. 2004. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113: 1515-1525.
3. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
4. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
5. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2: 52-58.
6. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, O. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4: 328-332.
7. Timmerman, J. M., and R. Levy. 1998. Melanoma vaccines: prim and proper presentation. Nat. Med. 4: 269-270.
8. Kim, D. 2000. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 19: 6660-6669.
9. Noguchi, Y., K. Sawaizumi, K. Ishiwara, and T. Saito. 1960. Virotherapy of skin cancers. I. Clinical effect of purified vaccine lymph on skin cancers. Yokohama Med. Bull. 11: 241-249.
10. Yonemitsu, Y., C. Kitson, S. Ferrari, R. Farley, U. Griesenbach, D. Judd, R. Steel, P. Scheid, J. Zhu, P. K. Jeffery, et al. 2000. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat. Biotechnol. 18: 970-973.
11. Masaki, L., Y. Yonemitsu, K. Komori, H. Ueno, Y. Nakashima, K. Nakagawa, M. Fukumura, A. Kato, M. K. Hasan, Y. Nagai, et al. 2001. Recombinant Sendai virus-mediated gene transfer to vasculature: a new class of efficient gene transfer vector to the vascular system. FASEB J. 15: 1294-1296.
12. Tsutsumi, N., Y. Yonemitsu, Y. Shikada, M. Onimaru, M. Tanii, S. Okano, K. Kaneko, M. Hasegawa, M. Hashizume, Y. Maehara, and K. Sueishi. 2004. Essential role of PDGFRα-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRα during angiogenesis. Circ. Res. 94: 1186-1194.
13. Nagai, Y. 1999. Paramyxovirus replication and pathogenesis: reverse genetics transforms understanding. Rev. Med. Virol. 9: 83-99.
14. Markwell, M. A., L. Svennerholm, and J. C. Paulson. 1981. Specific gangliosides function as host cell receptors for Sendai virus. Proc. Natl. Acad. Sci. USA 78: 5406-5410.
15. Moyer, S. A., S. C. Baker, and J. L. Lessard. 1986. Tubulin: a factor necessary for the synthesis of both Sendai virus and vesicular stomatitis virus RNAs. Proc. Natl. Acad. Sci. USA 83: 5405-5409.
16. Jin, C. H., K. Kusuhara, Y. Yonemitsu, A. Nomura, S. Okano, H. Takeshita, M., Hasegawa., K. Sueishi, and T. Hara T. 2003. Recombinant Sendai virus provides a highly efficient gene transfer into human cord blood-derived hematopoietic stem cells. Gene Ther. 10: 272-277.
17. Harada, N., M. Shimada, S. Okano, T. Suehiro, Y. Soejima, Y. Tomita, and Y. Maehara. 2004. IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. J. Immunol. 173: 6635-6644.
18. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176: 1693-1702.
19. Jackson, S. H., C. Alicea, J. W. Owens, C. L. Eigsti, and H. L. Malech. 2002. Characterization of an early dendritic cell precursor derived from murine lineage-negative hematopoietic progenitor cells. Exp. Hematol. 30: 430-439.
20. Spang-Thomsen, M., A. Nielsen, and J. Visfeldt. 1980. Growth curves of three human malignant tumors transplanted to nude mice. Exp. Cell Biol. 48: 138-154.
21. Bloom, M. B., D. Perry-Lalley, P. F. Robbins, Y. Li, M. el-Gamil, S. A. Rosenberg, and J. C. Yang. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185: 453-459.
22. Bellone, M., D. Cantarella, P. Castiglioni, M. C. Crosti, A. Roncherti, M. Moro, M. P. Garancini, G. Casorati, and P. Dellabona. 2000. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J. Immunol. 165: 2651-2656.
23. Dialynas, D. P., Z. S. Quan, K. A. Wall, A. Pierres, J. Quintans, M. R. Loken, M. Pierres, and F. W. Fitch. 1983. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J. Immunol. 131: 2445-2451.
24. Ledbetter, J. A., and L. A. Herzenberg. 1979. Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol. Rev. 47: 63-90.
25. Sauter, B., M. L. Albert, L. Francisco, M. Larsson, S. Somersan, and N. Bhardwaj. 2000. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191: 423-433.
26. Song, W., and R. Levy. 2005. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res. 65: 5958-5964.
27. Nagatani, T., S. Ichiyama, K. Miyakawa, and M. Uchiyama. 1992. Malignant melanoma treated with natural interferon α and β and DAV. Eur. J. Cancer 28A: 1774.
28. Hansen, R. M., and E. C. Borden. 1992. Current status of interferons in the treatment of cancer. Oncology 6: 19-24.
29. Vertuani, S., A. De Geer, V. Levitsky, P. Kogner, R. Kiessling, and J. Levitskaya. 2003. Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res. 63: 8006-8013.
30. + T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61: 8643-8646.
31. Nestle, F. O. 2000. Dendritic cell vaccination for cancer therapy. Oncogene 19: 6673-6679.
32. Strome, S. E., S. Voss, R. Wilcox, T. L. Wakefield, K. Tamada, D. Flies, A. Chapoval, J. Lu, J. L. Kasperbauer, D. Padley, et al. 2002. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. 62: 1884-1889.
33. Jonuleit, H., U. Kuhn, G. Muller, K. Steinbrink, L. Paragnik, E. Schmitt, J. Knop, and A. H. Enk. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27: 3135-3142.
34. Lopez, C. B., B. Moltedo, L. Alexopoulou, L. Bonifaz, R. A. Flavell, and T. M. Moran. 2004. TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses. J. Immunol. 173: 6882-6889.
35. Hiraoka, K., S. Yamamoto, S. Otsuru, S. Nakai, K. Tamai, R. Morishita, T. Ogihara, and Y. Kaneda. 2004. Enhanced tumor-specific long-term immunity of hemagglutinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J. Immunol. 173: 4297-4307.
36. Nakahara, S., T. Tsunoda, T. Baba, S. Asabe, and H. Tahara. 2003. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 63: 4112-4118.
37. Cromme, F. V., J. Airey, M. T. Heemels, H. L. Ploegh, P. J. Keating, P. L. Stern, C. J. Meijer, and J. M. Walboomers. 1994. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179: 335-340.
38. Cohen, E. P., and T. S. Ki. 1994. Neoplastic cells that express low levels of MHC class J determinants escape host immunity. Semin. Cancer Biol. 5: 419-428.
39. Speiser, D. E., R. Miranda, A. Zakarian, M. F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R. M. Zinkernagel, and P. S. Ohashi. 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186: 645-653.
40. Streckm, C. J., Y. Zhang, R. Miyamoto, J. Zhou, C. Y. C. Ng, A. C. Nathwani, and A. M. Davidoff. 2004. Restriction of neuroblastoma angiogenesis and growth by interferon-α/β. Surgery 136: 183-189.
41. O'Garra, A., and P. Vieira. 2004. Regulatory T cells and mechanisms of immune system control. Nat. Med. 10: 801-805.